• Molecular NameCefoxitin
  • SynonymNA
  • Weight427.458
  • Drugbank_IDDB01331
  • ACS_NO35607-66-0
  • Show 2D model
  • LogP (experiment)-0.02
  • LogP (predicted, AB/LogP v2.0)0.09
  • pkaN/A
  • LogD (pH=7, predicted)-3.78
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.57
  • LogSw (predicted, AB/LogsW2.0)1.86
  • Sw (mg/ml) (predicted, ACD/Labs)0.19
  • No.of HBond Donors4
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds8
  • TPSA201.8
  • StatusFDA approved
  • AdministrationIV
  • PharmacologyA cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second??generation cephalosporins.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmminimal, Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations.
  • Half life41-59 min
  • Excretion85% urine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityCefoxitin is generally well tolerated. The most common adverse reactions have been local reactions following intravenous injection (thrombophlebitis). Other adverse reactions have been encountered infrequently. They include allergic reactions, hypotension, gastrointestinal symptoms, exacerbation of myasthenia gravis, bone marrow depression, liver and renal function impairment.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A